Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus adjuvant chemotherapy versus adjuvant chemotherapy alone in resected triple-negative breast cancer
MOH_2018-10-03_000856Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Roche. Started Jul 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2018-10-03_000856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-03_000856.